Phase 3 Readout~month

Phase 3 Topline: A Randomized, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody-Drug Conjugate (ADC), Compared t

Indication
Small-cell Lung Cancer

Other upcoming events for ZLAB

Phase 3 ReadoutPhase 3 Topline: A Multicenter, Double-blinded, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Randomized, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody-Drug Conjugate (ADC), Compared t — ZLAB Phase 3 Readout | BioSniper